1254170-70-1 Usage
Description
5-Methoxy-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is a heterocyclic chemical compound with the molecular formula C11H11N3O3. It features an imidazole ring and a pyridine ring, and is an ethyl ester derivative of 5-methoxy-imidazo[1,2-a]pyridine-2-carboxylic acid. 5-Methoxy-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is known for its potential pharmacological properties and is commonly utilized in organic synthesis and pharmaceutical research. The presence of the ethyl ester group enhances its solubility and bioavailability, making it a valuable component in drug design and development.
Uses
Used in Pharmaceutical Research:
5-Methoxy-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a research compound for its potential pharmacological properties, including anti-inflammatory and antioxidant activities. It is being explored as a candidate for the treatment of various diseases due to these properties.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Methoxy-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a building block for the creation of more complex molecules and pharmaceutical agents. Its unique structure and functional groups make it a versatile component in the synthesis of new compounds.
Used in Drug Design and Development:
5-Methoxy-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is utilized as a key intermediate in drug design and development due to its increased solubility and bioavailability conferred by the ethyl ester group. This feature is crucial for improving the pharmacokinetic profile of new drug candidates, potentially leading to more effective therapeutic agents.
Used in the Development of Anti-Inflammatory Agents:
5-Methoxy-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester is used as a precursor in the development of anti-inflammatory agents. Its anti-inflammatory properties are being studied for potential applications in treating conditions characterized by inflammation.
Used in the Development of Antioxidant Therapies:
The antioxidant activity of this compound is being investigated for its potential use in antioxidant therapies, which could be beneficial in combating oxidative stress-related diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1254170-70-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,4,1,7 and 0 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1254170-70:
(9*1)+(8*2)+(7*5)+(6*4)+(5*1)+(4*7)+(3*0)+(2*7)+(1*0)=131
131 % 10 = 1
So 1254170-70-1 is a valid CAS Registry Number.
1254170-70-1Relevant articles and documents
4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE
-
Page/Page column 133, (2021/06/26)
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain H-APPAMP compounds (referred to herein as "H-APPAMP compounds") that, inter alia, inhibit cyclin-dependent protein kinases (CDKs), especially CDK12 and/or CDK13, and are selective, for example, for CDK12 and/or CDK13 as compared to CDK7. In addition to selectively inhibiting CDK12 and/or CDK13, the compounds also act as selective Cyclin K degraders thereby removing the key signaling mechanism required for CDK12 and/or CDK13 activation; this confers additional cellular potency and selectivity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK, especially CDK12 and/or CDK13; and to treat disorders including: disorders that are associated with CDK, especially CDK12 and/or CDK13; disorders that result from an inappropriate activity of a CDK, especially CDK12 and/or CDK13; disorders that are associated with CDK mutation, especially CDK12 and/or CDK13mutation; disorders that are associated with CDK overexpression, especially CDK12 and/or CDK13 overexpression; disorders that are associated with upstream pathway activation of CDK, especially CDK12 and/or CDK13; disorders that are ameliorated by the inhibition of CDK, especially CDK12 and/or CDK13; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); autoimmune disorders (including rheumatoid arthritis); and disorders caused by dysfunction of translation in cells (including muscular dystrophy). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti estrogen, an anti-androgen, a Her2 blocker, a cytotoxic chemotherapeutic agent, an agent stimulating the immune system, a checkpoint inhibitor, a DMA repair inhibitor, etc.
